World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
45
Citations
5578
World Ranking
4732
National Ranking
186

Wijnand Helfrich publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Wijnand Helfrich sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 69 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 174 publications — 25th percentile

25% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Wijnand Helfrich D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Wijnand Helfrich sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 163 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 45 D-Index — 6th percentile

6% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Wijnand Helfrich is affiliated with the University Medical Center Groningen in the Netherlands. Their research contributions primarily lie within the field of Medicine, with a particular focus on Immunology, Oncology, Radiology, Nuclear Medicine and Imaging, Physiology, and Molecular Biology.

Their research topics span diverse areas including:

  • CAR-T cell therapy research
  • Immunotherapy and immune responses
  • Adenosine and purinergic signaling
  • Nanoplatforms for cancer theranostics
  • Cytomegalovirus and herpesvirus research
  • Click chemistry and its applications
  • Radiopharmaceutical chemistry and applications

Some of their recent published papers are:

  • Neoantigen-based cancer vaccination using chimeric RNA-loaded dendritic cell-derived extracellular vesicles, 2022, Journal of Extracellular Vesicles
  • Bispecific antibody approach for EGFR-directed blockade of the CD47-SIRPα "don't eat me" immune checkpoint promotes neutrophil-mediated trogoptosis and enhances antigen cross-presentation, 2020, OncoImmunology
  • Bispecific antibody CD73xEpCAM selectively inhibits the adenosine-mediated immunosuppressive activity of carcinoma-derived extracellular vesicles, 2021, Cancer Letters
  • Modular Medical Imaging Agents Based on Azide-Alkyne Huisgen Cycloadditions: Synthesis and Pre-Clinical Evaluation of 18F-Labeled PSMA-Tracers for Prostate Cancer Imaging, 2020, Chemistry - A European Journal
  • Applications of Anti-Cytomegalovirus T Cells for Cancer (Immuno)Therapy, 2023, Cancers

Wijnand Helfrich has frequently collaborated with several co-authors throughout their career. Frequent collaborators include:

  • Douwe F. Samplonius
  • Emily M. Ploeg
  • Isabel Britsch
  • Anne Paulien van Wijngaarden
  • Mark A.J.M. Hendriks

Their work has appeared multiple times in prominent publication venues such as:

  • OncoImmunology
  • Cancers
  • Chemistry - A European Journal
  • Journal of Extracellular Vesicles
  • Cancer Letters

Best Publications

  • Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specific membrane antigen in lymph node and bone metastases of prostate cancer.

    Hildo J.K. Ananias;Marius C. van den Heuvel;Wijnand Helfrich;Igle J. de Jong

  • Therapeutic potential of Galectin-9 in human disease.

    Valerie R. Wiersma;Marco de Bruyn;Wijnand Helfrich;Edwin Bremer

  • A recombinant, fully human monoclonal antibody with antitumor activity constructed from phage-displayed antibody fragments

    Gerwin Huls;Iafm Heijnen;ME Cuomo;JC Koningsberger

  • Targeted induction of apoptosis for cancer therapy: current progress and prospects

    Edwin Bremer;Go van Dam;Bart Jan Kroesen;Lou de Leij

  • Simultaneous Inhibition of Epidermal Growth Factor Receptor (EGFR) Signaling and Enhanced Activation of Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Receptor-mediated Apoptosis Induction by an scFv:sTRAIL Fusion Protein with Specificity for Human EGFR

    Edwin Bremer;Douwe F. Samplonius;Linda van Genne;Marike H. Dijkstra

  • Target cell-restricted apoptosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7

    Edwin Bremer;Douwe F. Samplonius;Matthias Peipp;Linda van Genne

  • Carbon monoxide-Releasing Molecule-2 (CORM-2) attenuates acute hepatic ischemia reperfusion injury in rats

    Yunwei Wei;Yunwei Wei;Ping Chen;Marco de Bruyn;Weihui Zhang

  • Target cell-restricted and -enhanced apoptosis induction by a scFv:sTRAIL fusion protein with specificity for the pancarcinoma-associated antigen EGP2.

    Edwin Bremer;Jos Kuijlen;Douwe Samplonius;Henning Walczak

  • Wnt2 acts as a cell type-specific, autocrine growth factor in rat hepatic sinusoidal endothelial cells cross-stimulating the VEGF pathway.

    Daniel Klein;Alexandra Demory;Francis Peyre;Jens Kroll

  • Dual-Modality Image-Guided Surgery of Prostate Cancer with a Radiolabeled Fluorescent Anti-PSMA Monoclonal Antibody

    Susanne Lutje;Mark Rijpkema;Gerben M. Franssen;Giulio Fracasso

  • Fas Receptor Clustering and Involvement of the Death Receptor Pathway in Rituximab-Mediated Apoptosis with Concomitant Sensitization of Lymphoma B Cells to Fas-Induced Apoptosis

    Alja J. Stel;Bram ten Cate;Susan Jacobs;Jan Willem Kok

  • Nuclear imaging of prostate cancer with gastrin-releasing-peptide-receptor targeted radiopharmaceuticals.

    H. J. K. Ananias;de Igle Jan Jong;Rudi Dierckx;C. van de Wiele

  • A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability.

    B. ten Cate;Edwin Bremer;M. de Bruyn;Theo Bijma

  • Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo

    Marco de Bruyn;Anna A. Rybczynska;Yunwei Wei;Yunwei Wei;Michael Schwenkert

  • Review: on TRAIL for malignant glioma therapy?

    J. M. A. Kuijlen;E. Bremer;J. J. A. Mooij;W. F. A. den Dunnen

  • High-affinity recombinant phage antibodies to the pan-carcinoma marker epithelial glycoprotein-2 for tumour targeting

    RC Roovers;P Henderikx;Wijnand Helfrich;E van der Linden

  • Antibody-based fusion proteins to target death receptors in cancer

    Marco de Bruyn;Edwin Bremer;Wijnand Helfrich

  • Approaches to lung cancer treatment using the CD3E x GP-2-directed bispecific monoclonal antibody BIS-1

    Bart Kroesen;J Nieken;Dirk Sleijfer;Grietje Molema

  • Frequency of Th17 CD20+cells in the peripheral blood of rheumatoid arthritis patients is higher compared to healthy subjects

    Paul Eggleton;Edwin Bremer;Joanna M Tarr;Marco de Bruyn

  • Construction and characterization of a bispecific diabody for retargeting T cells to human carcinomas

    Wijnand Helfrich;Bart Jan Kroesen;Rob C. Roovers;Lidia Westers

Frequent Co-Authors

Rudi Dierckx
Rudi Dierckx University Medical Center Groningen
Grietje Molema
Grietje Molema University Medical Center Groningen
Hans W. Nijman
Hans W. Nijman University Medical Center Groningen
Paul Eggleton
Paul Eggleton University of Exeter
Georg H. Fey
Georg H. Fey University of Erlangen-Nuremberg
Hidde J. Haisma
Hidde J. Haisma University of Groningen
Otto C. Boerman
Otto C. Boerman Radboud University
Wim J.G. Oyen
Wim J.G. Oyen Humanitas University
Harald Wajant
Harald Wajant University of Würzburg
Wiktor Szymanski
Wiktor Szymanski University of Groningen

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a degree in Immunology opens doors to various healthcare and research careers, often supported by related nursing programs. For those interested in clinical work with quicker entry options, exploring the fastest and easiest LPN programs can be a practical starting point. These programs provide essential patient care skills in a short timeframe.

For advanced practice roles, becoming a Nurse Practitioner is a popular pathway. Understanding which nurse practitioner program is easiest can help prospective students find suitable programs that balance rigor with accessibility.

Among specialized fields, Psychiatric Mental Health Nurse Practitioners (PMHNPs) play a crucial role in mental health care. Prospective students should consider the best psychiatric mental health nurse practitioner programs online which offer strong clinical placements, ensuring valuable hands-on experience.

Cost is also an important factor when selecting online programs. Finding the cheapest psych NP programs online can make advanced education more accessible without compromising quality.

Best Scientists Citing Wijnand Helfrich

Trending Scientists

Recently Published Articles